Drug Profile
Research programme: kinase inhibitors - Carna Biosciences/Sumitomo Pharma
Latest Information Update: 02 Dec 2022
Price :
$50
*
At a glance
- Originator Carna Biosciences; Sumitomo Dainippon Pharma
- Developer Carna Biosciences; Sumitomo Pharma
- Class Antipsychotics; Neuroprotectants; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders; Psychiatric disorders
Most Recent Events
- 02 Dec 2022 Kinase inhibitors is still in research for Psychiatric-disorders and Neurological-disorders in Japan (Carna Biosciences pipeline, December 2022)
- 28 Apr 2022 No recent reports of development identified for research development in Neurological-disorders in Japan
- 28 Apr 2022 No recent reports of development identified for research development in Psychiatric-disorders in Japan